专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009003694A2 METHOD FOR TREATING DISEASES RELATED TO MITOCHONDRIAL DYSFUNCTION 审中-公开
标题翻译：治疗与线粒体功能障碍有关的疾病的方法
公开(公告)号：WO2009003694A2
公开(公告)日：2009-01-08
申请号：PCT/EP2008005400
申请日：2008-07-02
申请人： REICHERT ANDREAS , DUVEZIN-CAUBET STEPHANE , WAGENER JOHANNES , ZICK MICHAEL , LANGER THOMAS , KOPPEN MIRKO , NEUPERT WALTER
发明人： REICHERT ANDREAS , DUVEZIN-CAUBET STEPHANE , WAGENER JOHANNES , ZICK MICHAEL , LANGER THOMAS , KOPPEN MIRKO , NEUPERT WALTER
IPC分类号： A61K38/46 , A61P43/00
CPC分类号： C12Q1/42 , C12Q1/37 , G01N2500/04
摘要： The present invention relates to means and methods for therapeutic intervention of mitochondrial disorders or diseases, in particular to a method for the treatment, prevention and/or amelioration of a disorder or disease correlated with mitochondrial dysfunction, a mitochondrial disorder or disease or a disorder or disease characterized by an altered OPA1 processing. Thereby, a pharmaceutically active amount of a compound capable of modulating the activity of an oligomeric complex comprising Afg3?1 and/or Afg3?2 or (a) variant(s) thereof is administered to a patient in need of medical intervention. The present invention also relates to the use of an oligomeric complex comprising Afg3?1 and/or Afg3?2 or (a) variant(s) thereof for the preparation of a pharmaceutical composition for the mentioned therapeutic intervention. The present invention further relates to a method of screening for a compound capable of modulating the activity of an oligomeric complex comprising Afg3?1 and/or Afg3?2 or (a) variant(s) thereof comprising the use of OPA1.
摘要翻译：本发明涉及用于线粒体病症或疾病的治疗性干预的手段和方法，具体涉及用于治疗，预防和/或改善与线粒体功能障碍，线粒体病症或疾病或病症相关的病症或疾病的方法或以改变OPA1加工为特征的疾病。由此，将药物活性量的能够调节包含Afg3β1和/或Afg3β2的寡聚复合物或其（a）变体的活性的化合物的药物给予需要医学干预的患者。本发明还涉及包含Afg3β1和/或Afg3α2的寡聚复合物或（a）其变体在制备用于所述治疗干预的药物组合物中的用途。本发明进一步涉及筛选能够调节包含Afg3β1和/或Afg3β2的寡聚复合物或（a）其变体的活性的化合物的方法，包括使用OPA1。

2. 发明申请

WO2011073954A3 NOVEL ANTAGONIST ANTIBODIES AND THEIR FAB FRAGMENTS AGAINST GPVI AND USES THEREOF 审中-公开
标题翻译：新型拮抗剂抗体及其抗GPVI及其用途的FAB片段
公开(公告)号：WO2011073954A3
公开(公告)日：2012-03-08
申请号：PCT/IB2010055917
申请日：2010-12-17
申请人： SANOFI AVENTIS , BAURIN NICOLAS , BLANCHE FRANCIS , CAMERON BEATRICE , CORVEY CARSTEN , DABDOUBI TARIK , ENGEL CHRISTIAN , FLORIAN PETER , FOCKEN INGO , KROLL KATJA , KRUIP JOCHEN , LANGE CHRISTIAN , LANGER THOMAS , LORENZ MARTIN , MIKOL VINCENT , RAO ERCOLE , WONEROW PETER
发明人： BAURIN NICOLAS , BLANCHE FRANCIS , CAMERON BEATRICE , CORVEY CARSTEN , DABDOUBI TARIK , ENGEL CHRISTIAN , FLORIAN PETER , FOCKEN INGO , KROLL KATJA , KRUIP JOCHEN , LANGE CHRISTIAN , LANGER THOMAS , LORENZ MARTIN , MIKOL VINCENT , RAO ERCOLE , WONEROW PETER
IPC分类号： C07K16/28
CPC分类号： C07K16/28 , A61K2039/505 , C07K1/1075 , C07K16/2803 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： FR2009/113 PCT PATENT APPLICATION TITLE Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof SANOFI-AVENTIS ABSTRACT The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab. The invention concerns a method for prevention of platelet activation when an anti-GP VI Fab is used.
摘要翻译：本发明公开了特异性结合人血小板膜蛋白Glycoprotein VI（GPVI）及其单价片段或衍生物的新型抗体。本发明的抗体是来自杂交瘤克隆390的抗体及其能诱导GPVI消耗表型的片段抗体。这些抗体和Fab片段能够阻断胶原结合，从而阻止胶原的血小板活化。本发明还涉及用于产生所公开的抗体和Fab片段的杂交瘤克隆和表达质粒。本发明还涉及单价抗体片段用于制备用于治疗血栓形成和其它血管疾病的研究，诊断和免疫治疗剂的用途。本发明还涉及在C-末端具有分子的Fab，以及使用这种修饰的Fab预防用抗体识别Fab的方法。本发明涉及当使用抗GP VI Fab时预防血小板活化的方法。

3. 发明申请

WO2004004020A3 INTEGRATED CIRCUIT ON A QUARTZ SUBSTRATE 审中-公开
标题翻译： IC ON石英衬底
公开(公告)号：WO2004004020A3
公开(公告)日：2004-02-26
申请号：PCT/DE0302116
申请日：2003-06-25
申请人： SIEMENS AG , LANGER THOMAS
发明人： LANGER THOMAS
IPC分类号： H01L27/12 , H01L27/20 , H03H9/05
CPC分类号： H03H9/0542 , H01L27/12 , H01L27/20
摘要： The invention relates to a quartz substrate (QS) to which an integrated circuit (IS) is applied, said circuit being actively connected to the quartz substrate (QS). According to the invention, the quartz substrate (QS) carries out a double function, acting as both a mechanical oscillating element and a carrier substrate for the integrated circuit (IS). The invention reduces space requirements, increases the reliability and improves the mechanical stability of circuit systems which use quartz for electromechanical conversion.
摘要翻译：本发明涉及，应用到集成电路（IS）时，（QS）被连接到在操作连接在石英衬底石英衬底（QS）。在石英基板（QS）根据本发明的双功能满足。其充当机械振动元件，例如用于集成电路（IS）的载体基底。本发明减少了所需的空间，并在更高的可靠性的结果和切换使用对于机电转换的石英系统，以便更好的机械稳定性。

4. 发明申请

WO2012028133A2 APPARATUS FOR STABILIZATION OF MARINE VESSELS BY MEANS OF INFLATABLE BUOYANT BODIES 审中-公开
标题翻译： DEVICE船舶OVER充气体升力稳定价格
公开(公告)号：WO2012028133A2
公开(公告)日：2012-03-08
申请号：PCT/DE2011001546
申请日：2011-08-02
申请人： ASTRIUM GMBH , LANGER THOMAS , VON OSTROWSKI THORGE
发明人： LANGER THOMAS , VON OSTROWSKI THORGE
CPC分类号： B01J7/02 , B63B43/02 , B63B43/10 , B63B2043/126 , B63B2043/145 , B63C7/10 , B63C7/12
摘要： In the case of an apparatus for production of gas for filling buoyant bodies for bodies which are located in the water with gases stored in a compressed form, a compressed-gas reservoir is combined with a hot-gas generator, which is known per se. In this case, the hot-gas generator is arranged both inside the compressed-gas reservoir and outside it and, furthermore, the hot-gas generator can be integrated in a mixing chamber. The hot-gas generator is based on catalytic decomposition of a liquid energy carrier, preferably hydrazine, or generates the buoyancy gas by combustion or by the chemical reaction of a solid energy carrier, preferably lithium hydride, with the surrounding seawater. The compressed-gas reservoir is filled with a gas. The hot-gas generator is preferably designed such that, when the apparatus is activated, the cooling down of the compressed gas is compensated for by the heat generated by the hot-gas generator, or pressure is built up or decreased in a controlled manner within the compressed-gas reservoir.
摘要翻译：在用于与压缩气体存储在压缩气体存储与已知的热气发生器组合为浮力机构在水体的填充气体发生装置。热气体发生器可以由此既压缩气体贮存器内，并且是相同的，也热气发生器可以被集成到一个混合室的外部被设置。基于液体能量载体的催化分解，优选肼的热气体发生器，或由燃烧而产生的升力气体，或由一个固定的能量源，优选锂，与周围的海水的化学反应。该压缩气体存储填充有气体。热气体发生器的尺寸优选使得在该装置的启动时，压缩气体的冷却是通过热产生的热气发生器或者受控的压力建立或压力降低的偏移被压缩气体贮存器中创建的。

5. 发明申请

WO2010007408A3 INTERMEDIATES 2-(2-CHLORO-5-HYDROXY-4-METHYLCARBAMOYLPHENOXY)-2-METHYLPROPIONIC ACID TERT-BUTYL ESTER AND GLYCIDYL BENZENE SULFONATES OR SALTS THEREOF AND THE PROCESS FOR PREPARATION OF SAID INTERMEDIATES 审中-公开
标题翻译：中间体2-（2-氯-5-羟基-4-甲基氨基甲酰基苯氧基）-2-甲基丙酸叔丁酯和甘油基苯磺酸盐或其盐及制备所述中间体的方法
公开(公告)号：WO2010007408A3
公开(公告)日：2010-05-06
申请号：PCT/GB2009050833
申请日：2009-07-13
申请人： ASTRAZENECA AB , ASTRAZENECA UK LTD , CHILVERS KIRSTY , HOPES PHILLIP , LANGER THOMAS
发明人： CHILVERS KIRSTY , HOPES PHILLIP , LANGER THOMAS
IPC分类号： C07C231/02 , C07C235/60 , C07C309/29 , C07C309/39
CPC分类号： C07C231/02 , C07D303/34 , C07C235/60
摘要： The present invention relates to novel processes for the preparation of intermediate compounds which can be used to prepare therapeutic drugs. The invention relates to the intermediates 2-(2-Chloro-5-hydroxy-4-5 methylcarbamoylphenoxy)-2-methylpropionic acid tert-butyl ester and glycidyl benzene sulfonates or salts thereof. More specifically, the present invention relates to the intermediates 2-(2-Chloro-5-hydroxy-4-methylcarbamoylphenoxy)-2-methylpropionic acid tert-butyl ester and novel glycidyl benzene sulfonates of formula IV as defined below, useful in the preparation of 2-10 {2-Chloro-5-{[(2S)-3-(5-chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-2-hydroxypropyl]oxy}-4-[(methylamino)carbonyl]phenoxy}-2-methylpropanoic acid.
摘要翻译：本发明涉及制备可用于制备治疗药物的中间体化合物的新方法。本发明涉及中间体2-（2-氯-5-羟基-4-甲基氨基甲酰基苯氧基）-2-甲基丙酸叔丁酯和缩水甘油基苯磺酸盐或其盐。更具体地说，本发明涉及如下所定义的中间体2-（2-氯-5-羟基-4-甲基氨基甲酰基苯氧基）-2-甲基丙酸叔丁酯和新型缩水甘油苯磺酸盐，其用于制备的2- {2-氯-5 - {[（2S）-3-（5-氯-1'H，3H-螺[1-苯并呋喃-2,4'-哌啶] -1'-基） - 2-羟基丙基]氧基} -4 - [（甲基氨基）羰基]苯氧基} -2-甲基丙酸。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式